Innovating Works
IMI2-2015-05-02
IMI2-2015-05-02: Diabetic Kidney Disease Biomarkers (DKD-BM)
Specific Challenge:Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence are increasing. The 5-year survival of a dialysis patient with DKD is less than 25 percent—worse than most cancers—new treatments are desperately needed to slow and/or reverse disease in this high-risk patient population. In order for DKD trials to be more successful in the future, the research community will need to advance a concerted effort to identify personalized markers to identify patients at high risk of progression, to identify patient subpopulations that are likely to respond to candidate therapeutics and to provide early indications of potential safety issues linked to candidate therapeutic agents.
Sólo fondo perdido 15M €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 13-10-2015.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence are increasing. The 5-year survival of a dialysis patient with DKD is less than 25 percent—worse than most cancers—new treatments are desperately needed to slow and/or reverse disease in this high-risk patient population. In order for DKD trials to be more successful in the future, the research community will need to advance a concerted effort to identify personalized markers to identify patients at high risk of progression, to identify patient subpopulations that are likely to respond to candidate therapeutics and to provide early indications of potential safety issues linked to candidate therapeutic agents.


Scope:The objectives are to identify and validate candidate biomarkers and/or biomarker panels from existing longitudinal databases. Enhance the understanding of key driver pathways that accelerate progression of DKD, as well as pathways that enable & drive the pathogenesis of DKD in the overall context of diabetes itself. Asses differences between DKD associated with Type 1 DM and Type 2 DM. In... ver más

Specific Challenge:Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence are increasing. The 5-year survival of a dialysis patient with DKD is less than 25 percent—worse than most cancers—new treatments are desperately needed to slow and/or reverse disease in this high-risk patient population. In order for DKD trials to be more successful in the future, the research community will need to advance a concerted effort to identify personalized markers to identify patients at high risk of progression, to identify patient subpopulations that are likely to respond to candidate therapeutics and to provide early indications of potential safety issues linked to candidate therapeutic agents.


Scope:The objectives are to identify and validate candidate biomarkers and/or biomarker panels from existing longitudinal databases. Enhance the understanding of key driver pathways that accelerate progression of DKD, as well as pathways that enable & drive the pathogenesis of DKD in the overall context of diabetes itself. Asses differences between DKD associated with Type 1 DM and Type 2 DM. In parallel with this early work in biomarker identification and profiling of people with DKD, preclinical efforts will leverage longitudinal clinical database findings to identify better in vitro and in vivo models of DKD, identify predictive biomarkers for both efficacy and safety, and identify new druggable target pathways for future drug development. The overarching goal is to provide therapeutic developers with new tools that are acceptable to global regulators to enable and facilitate drug development (e.g. companion diagnostics).


Expected Impact:The overall Project is expected to significantly advance the understanding of the pathophysiology, heterogeneity and natural history of DKD in patients, improve the knowledge on translatable preclinical models for DKD, and facilitate the development of standardized biomarker panels with both prognostic and predictive capacity to serve as entry criteria for future clinical trial protocols evaluating novel therapies for DKD.


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence are increasing. The 5-year survival of a dialysis patient with DKD is less than 25 percent—worse than most cancers—new treatments are desperately needed to slow and/or reverse disease in this high-risk patient population. In order for DKD trials to be more successful in the future, the research community will need to advance a concerted effort to identify personalized markers to identify patients at high risk of progression, to identify patient subpopulations that are likely to respond to candidate therapeutics and to provide early indications of potential safety issues linked to candidate therapeutic agents. Specific Challenge:Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence are increasing. The 5-year survival of a dialysis patient with DKD is less than 25 percent—worse than most cancers—new treatments are desperately needed to slow and/or reverse disease in this high-risk patient population. In order for DKD trials to be more successful in the future, the research community will need to advance a concerted effort to identify personalized markers to identify patients at high risk of progression, to identify patient subpopulations that are likely to respond to candidate therapeutics and to provide early indications of potential safety issues linked to candidate therapeutic agents.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
The budget breakdown for this call is given at the end of the Call topics text in the Call Conditions section, as well as the following information:
List of countries and applicable rules for funding
 
Eligibility and admissibility conditions
 
Evaluation criteria and procedure, scoring and threshold: described in IMI2 Manual for submission, evaluation and grant award
 
Indicative timetable for evaluation and grant agreement
 
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard Evaluation form
IMI2 Model Grant Agreement 
 
Please read carefully all provisions below before the preparation of your application.
The budget breakdown for this call is given at the end of the Call topics text in the Call Conditions section, as well as the following information:
List of countries and applicable rules for funding
 
Eligibility and admissibility conditions
 
Evaluation criteria and procedure, scoring and threshold: described in IMI2 Manual for submission, evaluation and grant award
 
Indicative timetable for evaluation and grant agreement
 
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard Evaluation form
IMI2 Model Grant Agreement 
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
El presupuesto total de la convocatoria asciende a
Presupuesto total de la convocatoria.
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2015-05-two-stage Diabetic Kidney Disease Biomarkers (DKD-BM) Specific Challenge:Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence...
Sin info.
IMI2-2015-07-04 DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION
en consorcio: Specific Challenge:Age-related macular degeneration (AMD) is a chronic disease and among the leading causes of blindness world-wide. Current...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-01 VALIDATION OF TRANSLATIONAL IMAGING METHODS IN DRUG SAFETY ASSESSMENT (TRISTAN)
en consorcio: Specific Challenge:The development of imaging biomarkers both for the pre-clinic and the clinic has the potential to advance safety evaluati...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER
en consorcio: Specific Challenge:Paediatric cancer: 20% of all paediatric cancer remains incurable Long term side effects associated with treatment Can...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-03 PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN
en consorcio: Specific Challenge:Neuropathic pain (NP) is a widespread disease affecting 6-8% of the population, causing great misery, and incurring huge...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-07 INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS
en consorcio: Specific Challenge:By 2020, heart disease and stroke will become the leading causes of death and disability worldwide, with the number of fa...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de